Audentes Therapeutics Inc (NASDAQ:BOLD) VP Suyash Prasad sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $36.98, for a total value of $369,800.00. Following the sale, the vice president now owns 28,236 shares of the company’s stock, valued at $1,044,167.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Suyash Prasad also recently made the following trade(s):
- On Monday, February 25th, Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock. The stock was sold at an average price of $30.06, for a total value of $300,600.00.
NASDAQ BOLD opened at $39.00 on Friday. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -11.47 and a beta of 1.85. Audentes Therapeutics Inc has a fifty-two week low of $17.95 and a fifty-two week high of $46.18.
Several institutional investors have recently made changes to their positions in BOLD. Great Point Partners LLC acquired a new position in shares of Audentes Therapeutics in the 4th quarter valued at $35,346,000. Partner Fund Management L.P. lifted its stake in shares of Audentes Therapeutics by 94.4% in the 4th quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock valued at $64,413,000 after purchasing an additional 1,467,120 shares during the last quarter. BB Biotech AG acquired a new position in shares of Audentes Therapeutics in the 4th quarter valued at $16,404,000. Millennium Management LLC acquired a new position in shares of Audentes Therapeutics in the 4th quarter valued at $12,600,000. Finally, BlackRock Inc. lifted its stake in shares of Audentes Therapeutics by 15.8% in the 4th quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock valued at $63,418,000 after purchasing an additional 406,605 shares during the last quarter. 97.81% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $44.00 price target (up from $33.00) on shares of Audentes Therapeutics in a research report on Monday, March 18th. William Blair reissued a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, February 27th. ValuEngine raised Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Piper Jaffray Companies boosted their price objective on Audentes Therapeutics from $45.00 to $55.00 and gave the stock a “positive” rating in a research note on Monday, April 8th. Finally, Citigroup lowered Audentes Therapeutics from a “neutral” rating to a “sell” rating and boosted their price objective for the stock from $28.00 to $32.00 in a research note on Friday, April 26th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $39.92.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/17/audentes-therapeutics-inc-bold-vp-suyash-prasad-sells-10000-shares.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: What are popular range trading strategies?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.